Blog

Home  /  Outputs   /  EUnetHTA Joint Action 2 (2012-15)   /  Joint Assessment on Ramucirumab (Cyramza®) in combination with Paclitaxel as second-line treatment for adult patients with advanced gastric or gastro-oesophageal junction adenocarcinoma

Joint Assessment on Ramucirumab (Cyramza®) in combination with Paclitaxel as second-line treatment for adult patients with advanced gastric or gastro-oesophageal junction adenocarcinoma

The purpose of the assessment is to evaluate Ramucirumab (Cyramza®) in combination with Paclitaxel for the treatment of gastric cancer.

Final version of the assessment was published in March 2015

Below is the documentation provided by the Joint Assessment authoring team:

WP5-SA-4_RAMUCIRUMAB for the treatment of gastric cancer_APPENDIX_6_INCLUDED

Ramucirumab for the treatment of gastric cancer_Rapid REA_Final_Mar2015